Close
What would you like to look for?
Site search

25 July 2022

Mosanna Therapeutics AG, a Basel-based biotechnology company developing the advanced small molecule MOS118 (formerly know as AVE0118) for the treatment of metabolic obstructive sleep apnea, closes a Seed Financing Round led by Forty51 Ventures. The proceeds will be used for formulation and manufacturing optimization of MOS118 and for regulatory activities in preparation of the first Phase 1b clinical trial.
VISCHER advises Mosanna Therapeutics AG since its incorporation on all Swiss legal matters.

The VISCHER team includes Matthias Staehelin (Partner) and Timothy Woodtli (Associate), both Corporate/M&A.

Categories: Corporate and Commercial, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk

Authors

You are currently offline. Some pages or content may fail to load.